Should You Invest in Artivion (AORT) for a Long-Term Benefit?

Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Ultra Strategy” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy underperformed its benchmark index, the Russell 2000 Growth Index, in the third quarter. News of continuous interest rate hikes from the federal reserve negatively impacted growth companies’ stocks, and those in which the firm invested dragged the strategy’s performance in the quarter. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Wasatch Global Investors highlighted stocks like Artivion, Inc. (NYSE:AORT) in its Q3 2022 investor letter. Headquartered in Kennesaw, Georgia, Artivion, Inc. (NYSE:AORT) provides medical devices and implantable human tissues worldwide. On December 9, 2022, Artivion, Inc. (NYSE:AORT) stock closed at $12.97 per share. One-month return of Artivion, Inc. (NYSE:AORT) was 3.76%, and its shares lost 29.16% of their value over the last 52 weeks. Artivion, Inc. (NYSE:AORT) has a market capitalization of $523.074 million.

Wasatch Global Investors made the following comment about Artivion, Inc. (NYSE:AORT) in its Q3 2022 investor letter:

“Artivion, Inc. (NYSE:AORT) was the largest detractor from strategy performance for the quarter. A medical-device company, Artivion develops solutions for the surgical treatment of aortic heart disease. The company’s shares tumbled after Artivion halted a clinical trial designed to determine If patients with its mechanical aortic valve could be maintained safely and effectively on apixaban—a next-generation blood thinner—rather than on warfarin. A successful trial would have significantly increased the company’s addressable market beginning in 2025. Despite the setback, Artivion’s aortic valve provides significant clinical benefits and remains the only mechanical aortic valve for which patients can be safely managed with reduced blood thinners.”

egyjanek/Shutterstock.com

Artivion, Inc. (NYSE:AORT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held Artivion, Inc. (NYSE:AORT) at the end of the third quarter, which was 11 in the previous quarter. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

• 25 Largest Shopping Malls in the US
• 15 Biggest Japanese Companies in USA
• 15 Richest Hedge Fund Managers in the World

Disclosure: None. This article is originally published at Insider Monkey.